Correlation Between Vaxcyte and Lyra Therapeutics

Can any of the company-specific risk be diversified away by investing in both Vaxcyte and Lyra Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vaxcyte and Lyra Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Vaxcyte and Lyra Therapeutics, you can compare the effects of market volatilities on Vaxcyte and Lyra Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vaxcyte with a short position of Lyra Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vaxcyte and Lyra Therapeutics.

Diversification Opportunities for Vaxcyte and Lyra Therapeutics

0.74

Correlation Coefficient

Vaxcyte  Lyra Therapeutics

Poor diversification

The 3 months correlation between Vaxcyte and Lyra is 0.74. Overlapping area represents the amount of risk that can be diversified away by holding Vaxcyte and Lyra Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lyra Therapeutics and Vaxcyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vaxcyte are associated (or correlated) with Lyra Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lyra Therapeutics has no effect on the direction of Vaxcyte i.e., Vaxcyte and Lyra Therapeutics go up and down completely randomly.

Pair Corralation between Vaxcyte and Lyra Therapeutics

Given the investment horizon of 90 days Vaxcyte is expected to under-perform the Lyra Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Vaxcyte is 2.61 times less risky than Lyra Therapeutics. The stock trades about -0.23 of its potential returns per unit of risk. The Lyra Therapeutics is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  21.00  in Lyra Therapeutics on October 5, 2024 and sell it today you would earn a total of  1.00  from holding Lyra Therapeutics or generate 4.76% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Vaxcyte  vs.  Lyra Therapeutics

Vaxcyte

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Vaxcyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Lyra Therapeutics

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Lyra Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Lyra Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Vaxcyte and Lyra Therapeutics

The main advantage of trading using opposite Vaxcyte and Lyra Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vaxcyte position performs unexpectedly, Lyra Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lyra Therapeutics will offset losses from the drop in Lyra Therapeutics' long position.

The idea behind Vaxcyte and Lyra Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.